Boston Partners boosted its stake in Globus Medical, Inc. (NYSE:GMED - Free Report) by 119.7% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,415,554 shares of the medical device company's stock after buying an additional 1,860,564 shares during the quarter. Boston Partners owned approximately 2.54% of Globus Medical worth $255,898,000 as of its most recent filing with the SEC.
Several other hedge funds have also recently bought and sold shares of the business. Elevation Wealth Partners LLC raised its stake in shares of Globus Medical by 2,178.6% in the 2nd quarter. Elevation Wealth Partners LLC now owns 319 shares of the medical device company's stock valued at $25,000 after buying an additional 305 shares in the last quarter. Continuum Advisory LLC purchased a new position in shares of Globus Medical in the second quarter valued at approximately $25,000. Root Financial Partners LLC purchased a new position in shares of Globus Medical in the 3rd quarter valued at $29,000. Heritage Family Offices LLP purchased a new position in shares of Globus Medical in the third quarter worth approximately $31,000. Finally, Jacobi Capital Management LLC bought a new stake in Globus Medical during the third quarter worth about $40,000. Hedge funds and other institutional investors own 95.16% of the company's stock.
Analysts Set New Price Targets
Several brokerages have recently commented on GMED. Canaccord Genuity Group lowered their target price on shares of Globus Medical from $115.00 to $105.00 and set a "buy" rating on the stock in a report on Friday, November 6th. UBS Group assumed coverage on Globus Medical in a report on Tuesday, July 28th. They issued a "neutral" rating and a $82.00 target price for the company. Wells Fargo & Company raised their price target on shares of Globus Medical from $99.00 to $100.00 and gave the company an "overweight" rating in a research report on Friday, November 6th. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Globus Medical in a report on Friday, October 9th. Finally, Needham & Company LLC reduced their price objective on Globus Medical from $117.00 to $100.00 and set a "buy" rating for the company in a report on Friday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $96.08.
Get Our Latest Report on GMED
Insider Activity at Globus Medical
In other news, Director James Tobin sold 41,666 shares of the company's stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $75.16, for a total transaction of $3,131,616.56. Following the completion of the sale, the director directly owned 15,000 shares in the company, valued at $1,127,400. This represents a 73.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Ann D. Rhoads sold 5,000 shares of the company's stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $85.00, for a total value of $425,000.00. Following the completion of the sale, the director directly owned 35,384 shares of the company's stock, valued at $3,007,640. The trade was a 12.38% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 76,666 shares of company stock worth $5,794,017 in the last quarter. 18.38% of the stock is currently owned by insiders.
Globus Medical Trading Down 2.8%
Shares of NYSE:GMED opened at $68.56 on Friday. The stock has a market capitalization of $9.08 billion, a P/E ratio of 14.19, a price-to-earnings-growth ratio of 1.09 and a beta of 0.98. Globus Medical, Inc. has a 12-month low of $68.25 and a 12-month high of $101.40. The stock's 50-day moving average price is $76.13 and its 200-day moving average price is $82.29.
Globus Medical (NYSE:GMED - Get Free Report) last announced its earnings results on Thursday, November 5th. The medical device company reported $1.23 earnings per share for the quarter, beating analysts' consensus estimates of $1.20 by $0.03. Globus Medical had a net margin of 17.76% and a return on equity of 14.43%. The firm had revenue of $763.72 million for the quarter, compared to analyst estimates of $792.39 million. During the same quarter in the previous year, the firm posted $1.18 EPS. The company's revenue for the quarter was down .7% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. As a group, research analysts predict that Globus Medical, Inc. will post 4.98 EPS for the current year.
About Globus Medical
(
Free Report)
Globus Medical is a medical device company focused on musculoskeletal care. Its products include implants and instruments used in spine surgery, as well as solutions for orthopedic trauma and other orthopedic procedures. The company also develops surgical technologies, including robotic navigation and imaging systems designed to support planning and guidance during procedures. Its portfolio expanded significantly in 2023 when Globus Medical completed its combination with NuVasive, a provider of spine care products and technologies.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Globus Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Globus Medical wasn't on the list.
While Globus Medical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.